Results 21 to 30 of about 28,700 (297)

Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol in the management of primary open angle glaucoma [PDF]

International Journal of Ophthalmology, 2014
AIM:To evaluate intraocular pressure (IOP)-lowering effect and ocular tolerability of brimonidine/timolol, dorzolamide/timolol and latanoprost/timolol fixed combination therapies in the management of primary open angle glaucoma.METHODS:Each drug was ...
Murat Atabey Ozer, Mutlu Acar, Cem Yildirim   +2 more
doaj   +1 more source

A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine [PDF]

, 2020
Introduction. Daily oral beta-adrenoreceptor antagonist has been shown to be effective in preventing migraine headaches. Timolol 0.5% ophthalmic solution is a non-selective beta-adrenoreceptor antago- nist, where the primary use is for glaucoma.
Aggarwal, Dipika, Barohn, Richard J., Bittel, Brennen, Dubinsky, Richard, Ford, Deetra, Gronseth, Gary, Hairston, Vernita, Heim, Andrew J., Herbelin, Laura, Landazuri, Patrick, Sachen, Fred   +10 more
core   +2 more sources

A COMPARATIVE STUDY OF DORZOLAMIDE + TIMOLOL VS. BRIMONIDINE + TIMOLOL FIXED COMBINATION THERAPY IN THE MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA [PDF]

, 2017
Background: To compare the efficiency of dorzolamide + timolol fixed combination vs. the Brimonidine + timolol fixed combination in the management of primary open-angle glaucoma Materials and methods: A prospective study conducted over a period
Ramniklal Savalia, Pratik
core   +4 more sources

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. [PDF]

, 2005
BACKGROUND: Nonselective beta-adrenergic blockers decrease portal pressure and prevent variceal hemorrhage. Their effectiveness in preventing varices is unknown.
Bosch, J, Burroughs, AK, Escorsell, A, Gao, H, Garcia-Pagan, JC, Garcia-Tsao, G, Grace, ND, Groszmann, RJ, Makuch, R, Matloff, DS, Patch, D, Planas, R, Portal Hypertension Collaborative Group   +12 more
core   +1 more source

Pharmacogenetics of ophthalmic topical β-blockers [PDF]

, 2008
Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure.
McCarty, Catherine A., Patchett, Richard, Sidjanin, Duska J., Smith, Edward M., Wilke, Russell A.   +4 more
core   +1 more source

Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study

BMJ Open, 2019
Objectives Bimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as ...
R. Bourne, K. Kaarniranta, K. Lorenz, C. Traverso, J. Vuorinen, A. Ropo   +5 more
semanticscholar   +1 more source

Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma

Indian Journal of Ophthalmology, 2013
The aim of present study was to compare the efficacy and safety of fixed combination of brimonidine and timolol with individual components used as monotherapy in patients of primary open angle glaucoma.
Sachin R Joshi, Pramod B Akat, Jaiprakash B Ramanand, Sunita J Ramanand, Vitthal B Karande, Suyog S Jain   +5 more
doaj   +1 more source

Sinus bradycardia following single-day use of timolol eye drops in a healthy young adult - A rare case report

Journal of Clinical Ophthalmology and Research, 2021
We report the rare case of timolol-induced sinus bradycardia in an otherwise healthy young individual following just 1 day use of timolol eye drops.
Sandip Sarkar, Pragathi Shankaralingappa, Amit Kumar Deb, Sangaraju Suneel, Subashini Kaliaperumal, Kaviyapriya Natarajan, Sasikumar Mahalingam   +6 more
doaj   +1 more source

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.

PLoS ONE, 2022
PurposeTo evaluate the concentrations of brimonidine and timolol in the vitreous and aqueous humors after instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution.MethodsThis single-arm open-label interventional ...
Yusuke Orii, Eriko Kunikane, Yutaka Yamada, Masakazu Morioka, Kentaro Iwasaki, Shogo Arimura, Akemi Mizuno, Masaru Inatani   +7 more
doaj   +2 more sources

Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device.

Journal of Ocular Pharmacology and Therapeutics, 2019
PURPOSE We developed a polycaprolactone (PCL) co-delivery implant that achieves zero-order release of 2 ocular hypotensive agents, timolol maleate and brimonidine tartrate.
Karen E. Samy, Yiqi Cao, Jean Kim, N. R. Konichi da Silva, Audrey Phone, M. Bloomer, R. Bhisitkul, T. Desai   +7 more
semanticscholar   +1 more source